Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors

被引：39
作者：
Abdallah, Abdallah E. [1 ]
Mabrouk, Reda R. [1 ]
Al Ward, Maged Mohammed Saleh [1 ]
Eissa, Sally, I [2 ,3 ]
Elkaeed, Eslam B. [3 ]
Mehany, Ahmed B. M. [4 ]
Abo-Saif, Mariam A. [5 ]
El-Feky, Ola A. [5 ]
Alesawy, Mohamed S. [1 ]
El-Zahabi, Mohamed Ayman [1 ]
机构：
[1] Al Azhar Univ, Fac Pharm Boys, Pharmaceut Med Chem & Drug Design Dept, Cairo, Egypt
[2] Al Azhar Univ, Fac Pharm Girls, Dept Pharmaceut Chem, Cairo, Egypt
[3] AlMaarefa Univ, Coll Pharm, Dept Pharmaceut Sci, Riyadh, Saudi Arabia
[4] Al Azhar Univ, Fac Sci, Zool Dept, Cairo, Egypt
[5] Tanta Univ, Fac Pharm, Biochem Dept, Tanta, Egypt
来源：
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY | 2022年 / 37卷 / 01期
关键词：
Anticancer; apoptosis; multi-kinase; pharmacophoric features; VEGFR-2; KINASE INHIBITORS; DISCOVERY; CANCER; DERIVATIVES; MECHANISMS; BINDING;
D O I：
10.1080/14756366.2021.2017911
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Based on quinazoline, quinoxaline, and nitrobenzene scaffolds and on pharmacophoric features of VEGFR-2 inhibitors, 17 novel compounds were designed and synthesised. VEGFR-2 IC50 values ranged from 60.00 to 123.85 nM for the new derivatives compared to 54.00 nM for sorafenib. Compounds 15(a) , 15(b) , and 15(d) showed IC50 from 17.39 to 47.10 mu M against human cancer cell lines; hepatocellular carcinoma (HepG2), prostate cancer (PC3), and breast cancer (MCF-7). Meanwhile, the first in terms of VEGFR-2 inhibition was compound 15(d) which came second with regard to antitumor assay with IC50 = 24.10, 40.90, and 33.40 mu M against aforementioned cell lines, respectively. Furthermore, Compound 15(d) increased apoptosis rate of HepG2 from 1.20 to 12.46% as it significantly increased levels of Caspase-3, BAX, and P53 from 49.6274, 40.62, and 42.84 to 561.427, 395.04, and 415.027 pg/mL, respectively. Moreover, 15(d) showed IC50 of 253 and 381 nM against HER2 and FGFR, respectively.
引用
收藏
页码：573 / 591
页数：19
相关论文
共 49 条
[1]   Novel Nanocombinations of l-Tryptophan and l-Cysteine: Preparation, Characterization, and Their Applications for Antimicrobial and Anticancer Activities [J].
Abd-Elhamid, Ahmed I. ;
El-Gendi, Hamada ;
Abdallah, Abdallah E. ;
El-Fakharany, Esmail M. .
PHARMACEUTICS, 2021, 13 (10)
[2]   Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening [J].
Abdallah, Abdallah E. ;
Alesawy, Mohamed S. ;
Eissa, Sally I. ;
El-Fakharany, Esmail M. ;
Kalaba, Mohamed H. ;
Sharaf, Mohamed H. ;
Abo Shama, Noura M. ;
Mahmoud, Sara H. ;
Mostafa, Ahmed ;
Al-Karmalawy, Ahmed A. ;
Elkady, Hazem .
NEW JOURNAL OF CHEMISTRY, 2021, 45 (36) :16557-16571
[3]   Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation [J].
Abdallah, Abdallah E. ;
Eissa, Sally, I ;
Al Ward, Maged Mohammed Saleh ;
Mabrouk, Reda R. ;
Mehany, Ahmed B. M. ;
El-Zahabi, Mohamed Ayman .
BIOORGANIC CHEMISTRY, 2021, 109
[4]   Identification of new pyrrolo [2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling [J].
Adel, Mai ;
Serya, Rabah A. T. ;
Lasheen, Deena S. ;
Abouzid, Khaled A. M. .
BIOORGANIC CHEMISTRY, 2018, 81 :612-629
[5]   In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (Mpro) [J].
Alesawy, Mohamed S. ;
Abdallah, Abdallah E. ;
Taghour, Mohammed S. ;
Elkaeed, Eslam B. ;
H. Eissa, Ibrahim ;
Metwaly, Ahmed M. .
MOLECULES, 2021, 26 (09)
[6]   Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors [J].
Alesawy, Mohamed S. ;
Al-Karmalawy, Ahmed A. ;
Elkaeed, Eslam B. ;
Alswah, Mohamed ;
Belal, Ahmed ;
Taghour, Mohammed S. ;
Eissa, Ibrahim H. .
ARCHIV DER PHARMAZIE, 2021, 354 (03)
[7]   Molecular mechanisms of lymphangiogenesis in health and disease [J].
Alitalo, K ;
Carmeliet, P .
CANCER CELL, 2002, 1 (03) :219-227
[8]   Synthesis and structure of N-alkyl(aryl)aminocarbonyl-1,4-benzoquinone imines [J].
Avdeenko, A. P. ;
Konovalova, S. A. ;
Sergeeva, A. G. ;
Zubatyuk, R. I. ;
Palamarchuk, G. V. ;
Shishkin, O. V. .
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, 2008, 44 (12) :1765-1772
[9]   Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents [J].
Aziz, Marwa A. ;
Serya, Rabah A. T. ;
Lasheen, Deena S. ;
Abdel-Aziz, Amal Kamal ;
Esmat, Ahmed ;
Mansour, Ahmed M. ;
Singab, Abdel Nasser B. ;
Abouzid, Khaled A. M. .
SCIENTIFIC REPORTS, 2016, 6
[10]   Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design [J].
Blanc, Javier ;
Geney, Raphael ;
Menet, Christel .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (05) :731-747
12345